WO2010129138A3 - Phosphorylated and phosphonated pyrone analogs for therapeutic treatment - Google Patents

Phosphorylated and phosphonated pyrone analogs for therapeutic treatment Download PDF

Info

Publication number
WO2010129138A3
WO2010129138A3 PCT/US2010/030613 US2010030613W WO2010129138A3 WO 2010129138 A3 WO2010129138 A3 WO 2010129138A3 US 2010030613 W US2010030613 W US 2010030613W WO 2010129138 A3 WO2010129138 A3 WO 2010129138A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
derivative
prevention
treatment
phosphonated
Prior art date
Application number
PCT/US2010/030613
Other languages
French (fr)
Other versions
WO2010129138A2 (en
Inventor
May Dean-Ming Lee
Ving Lee
Wendye Robbins
Original Assignee
Limerick Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Limerick Biopharma, Inc. filed Critical Limerick Biopharma, Inc.
Priority to JP2012507250A priority Critical patent/JP2012525331A/en
Priority to EP10714412A priority patent/EP2424541A2/en
Publication of WO2010129138A2 publication Critical patent/WO2010129138A2/en
Publication of WO2010129138A3 publication Critical patent/WO2010129138A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Abstract

Methods are described for the treatment and prevention of metabolic disorders or other diseases by administering a pyrone analog or a derivative thereof Methods are also described for the treatment and prevention of metabolic disorders and other diseases by administering a pyrone analog, or a derivative thereof, in combination with one or more additional agents such as, for example, lipid lowering agents or glucose lowering agents Methods are described for the modulation of lipid transporter activity to increase the efflux of lipid from a physiological compartment into an external environment Methods disclosed herein may be used to assess treatment or prevention of a metabolic disorder following administration of a pyrone analog or a derivative thereof.
PCT/US2010/030613 2009-04-27 2010-04-09 Phosphorylated and phosphonated pyrone analogs for therapeutic treatment WO2010129138A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2012507250A JP2012525331A (en) 2009-04-27 2010-04-09 Phosphorylated pyrone analogs for therapeutic treatment
EP10714412A EP2424541A2 (en) 2009-04-27 2010-04-09 Phosphorylated and phosphonated pyrone analogs for therapeutic treatment

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17316909P 2009-04-27 2009-04-27
US61/173,169 2009-04-27
US22518309P 2009-07-13 2009-07-13
US61/225,183 2009-07-13
US24311109P 2009-09-16 2009-09-16
US61/243,111 2009-09-16

Publications (2)

Publication Number Publication Date
WO2010129138A2 WO2010129138A2 (en) 2010-11-11
WO2010129138A3 true WO2010129138A3 (en) 2011-12-29

Family

ID=42227709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/030613 WO2010129138A2 (en) 2009-04-27 2010-04-09 Phosphorylated and phosphonated pyrone analogs for therapeutic treatment

Country Status (3)

Country Link
EP (1) EP2424541A2 (en)
JP (1) JP2012525331A (en)
WO (1) WO2010129138A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2473150A (en) * 2007-07-31 2011-03-02 Limerick Biopharma Inc Quercetin-3'-O-phosphate
WO2009018338A2 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
EP2718277A4 (en) * 2011-06-06 2015-02-11 Cardero Therapeutics Inc Methods and compositions for treatment of mitochondrial toxicity
US20140088372A1 (en) * 2012-09-25 2014-03-27 Google Inc. Information processing method
DK2906578T3 (en) 2012-10-11 2019-07-15 Armaron Bio Pty Ltd HOWEVER, Unknown FLAVONOID CONNECTIONS AND USES THEREOF
CN103641807B (en) * 2013-12-25 2015-12-09 南通大学 A kind of extracting method of apigenin, the pharmaceutical composition being used for the treatment of diabetes and application thereof
US9260461B2 (en) * 2014-02-03 2016-02-16 Versitech Limited Water-soluble derivatives and prodrugs of acacetin and methods of making and using thereof
CN104530127B (en) * 2014-12-12 2016-09-14 广东东阳光药业有限公司 A kind of two derivatives from icariin and investigation and using method thereof and purposes
CN104860993B (en) * 2015-05-22 2017-08-22 北京盛诺基医药科技有限公司 A kind of chromocor compound prodrug and application thereof
CN108465002A (en) * 2018-06-21 2018-08-31 黑龙江中医药大学 A kind of pharmaceutical composition that treating atherosclerosis and its application
CN109045014B (en) * 2018-07-02 2021-02-26 宁夏医科大学 Application of vitexin in preparing medicine for treating diabetic function and low fertility
CN108752378A (en) * 2018-07-12 2018-11-06 四川福思达生物技术开发有限责任公司 A kind of synthetic method of methyl hypophosphorous acid monoalkyl ester
EP3594209A1 (en) * 2018-07-13 2020-01-15 Centre National De La Recherche Scientifique (Cnrs) Lipophenolic flavonoid derivatives useful to reduce carbonyl and oxidative stresses (cos)
KR102349477B1 (en) * 2019-08-30 2022-01-10 (주)프론트바이오 Pharmaceutical composition for preventing or treating cancer comprising biguanides, and flavone, hydroxyflavone, flvanone, flavone derivatives, hydroxyflavone derivatives, flavanone derivatives as active ingredients
CN112481314B (en) * 2020-12-04 2022-09-06 江南大学 Method for preparing inhibitor for inhibiting activities of alpha-amylase and glucosidase
CN113440514B (en) * 2021-08-20 2022-09-09 中国农业科学院郑州果树研究所 Composition containing hesperetin and application thereof in preparation of hypoglycemic drugs
KR102630951B1 (en) * 2022-05-18 2024-01-29 제주대학교 산학협력단 Composition for anti-inflammation comprising 5-hydroxymaltol

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0666265A1 (en) * 1993-08-20 1995-08-09 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
WO2003022994A2 (en) * 2001-09-06 2003-03-20 Synorx, Inc. Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto
US20040059136A1 (en) * 2000-10-06 2004-03-25 Jean-Pierre Gesson 7-carboxy-flavone derivatives preparation method and therapeutic use
WO2004037193A2 (en) * 2002-10-22 2004-05-06 Jenken Biosciences, Inc. Chromones and chromone derivatives and uses thereof
DE102006050925A1 (en) * 2006-10-28 2008-04-30 Merck Patent Gmbh New ((4-oxo-4H-chromen-3-yl)-hydroxymethyl)- or ((4-oxo-4H-chromen-3-yl)-methyl)-phosphoric acid derivatives are elastase inhibitors useful e.g. to prepare a preparation exhibiting protecting effect against oxidative stress on body cells
WO2008150085A2 (en) * 2007-06-07 2008-12-11 Dong-A Pharm. Co., Ltd. 3',4',5-trimethoxy flavone derivatives as stimulant of mucus secretion, method of the same, and pharmaceutical composition comprising the same
WO2009018338A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
WO2010134082A1 (en) * 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0666265A1 (en) * 1993-08-20 1995-08-09 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
US20040059136A1 (en) * 2000-10-06 2004-03-25 Jean-Pierre Gesson 7-carboxy-flavone derivatives preparation method and therapeutic use
WO2003022994A2 (en) * 2001-09-06 2003-03-20 Synorx, Inc. Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto
WO2004037193A2 (en) * 2002-10-22 2004-05-06 Jenken Biosciences, Inc. Chromones and chromone derivatives and uses thereof
DE102006050925A1 (en) * 2006-10-28 2008-04-30 Merck Patent Gmbh New ((4-oxo-4H-chromen-3-yl)-hydroxymethyl)- or ((4-oxo-4H-chromen-3-yl)-methyl)-phosphoric acid derivatives are elastase inhibitors useful e.g. to prepare a preparation exhibiting protecting effect against oxidative stress on body cells
WO2008150085A2 (en) * 2007-06-07 2008-12-11 Dong-A Pharm. Co., Ltd. 3',4',5-trimethoxy flavone derivatives as stimulant of mucus secretion, method of the same, and pharmaceutical composition comprising the same
WO2009018338A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
WO2010134082A1 (en) * 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer

Also Published As

Publication number Publication date
JP2012525331A (en) 2012-10-22
EP2424541A2 (en) 2012-03-07
WO2010129138A2 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
WO2010129138A3 (en) Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
WO2010042886A3 (en) Pyrones for the treatment of metabolic disorders
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2013004699A (en) Pharmaceutical combinations for the treatment of metabolic disorders.
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
WO2007136518A3 (en) Treatment of autoimmune disorders
WO2008070346A3 (en) Methods for treating pain with reduced nuasea and vomiting
BR112013024973A2 (en) prevention of hypoglycemia in patients with type 2 diabetes mellitus
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
WO2012055967A3 (en) Treating diabetes melitus using insulin injections administered with varying injection intervals
WO2009018326A3 (en) Soluble pyrone analogs methods and compositions
EA021275B9 (en) Heterocyclic compounds, pharmaceutical composition comprising same and use thereof for treatment of pask-mediated disease
WO2012129112A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2009068659A3 (en) Novel disease treatment by predicting drug association
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2008149802A1 (en) Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient
WO2012119046A3 (en) Heterocyclic compounds for the inhibition of pask
AU2012366182A8 (en) Method of treating diabetes using non-glycosylated apolipoprotein A-IV
WO2012094462A3 (en) Heterocyclic compounds for the inhibition of pask
WO2013155528A3 (en) Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels
WO2007070355A3 (en) Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
PH12014501646A1 (en) Substituted phenylazole derivative
CA2688047A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10714412

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012507250

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010714412

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE